Microsulis Medical (MML), a provider of microwave technology for medical devices, has launched Acculis percutaneous microwave tissue ablation system, Accu2i pMTA, at the second European Conference on Interventional Oncology (ECIO) in Florence, Italy.
MML’s Accu2i is a 1.8mm diameter closed water-cooled needle, with performance matching the existing Acculis open surgery MTA system and acts as a new device for destroying tumours.
The device brings the benefits of microwave ablation to the interventional radiologist with applications in liver, lung, bone, kidney and appropriate other sites where local tumour control can be safely secured using volume ablation.
MML claimed that the Accu2i pMTA is the tumour ablation system currently available, combining extreme ease of use with the widest range of clinical applications. The device is a single high power high frequency 2.45GHz microwave needle that can address tumours over 5cm in size in just 6 minutes, and is therefore between 3 to 10 times faster than other systems.
MML said that the launch follows two years of clinical use and evaluation around the world in major liver centres in the US, Asia-Pacific, UK and Europe. It was CE-marked in February 2010 and further international regulatory clearances are expected shortly.
Stuart McIntyre, CEO of Microsulis, said: “The conference has been an extremely successful launch for us. As well as introducing the Accu2i to a wider clinical audience, many further international distributors have now been engaged, thereby expanding the worldwide distribution network for the product.
“This is especially pleasing to us, as it is the latest in a series of product innovations, based on the unique Acculis MTA technology all developed and patented in the UK.”